Tuesday, September 1, 2009

Website: www.ceragenix.com (see also www.epiceram.com for description of Company’s first commercialized product).

Partner Exercises Option for Exclusive Period to Negotiate Licensing Terms for CeraShieldTM Antimicrobial Coating Application.

DENVER, september 1, 2009 -- Ceragenix Pharmaceuticals, Inc. ("Ceragenix" or the "Company") (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today provided an update to a previously announced exclusive evaluation and option to license agreement (the "Agreement") with a global, multi-billion dollar healthcare company covering the use of the Company's CerashieldTM antimicrobial technology for a specific medical device associated with a high incidence of hospital acquired infections. Ceragenix announced that it has been notified by this potential partner that it has successfully completed its initial evaluation and has decided to invoke its right to negotiate commercialization terms pursuant to the terms of the Agreement. Under the terms of the Agreement, the partner now has an exclusive ninety (90) day period to negotiate a license agreement for the CerashieldTM technology within the field of use as defined in the Agreement. There is no assurance that the parties will be able to reach an agreement on the terms of a license agreement. For competitive reasons, neither the name of the company nor the precise field of use has been publicly disclosed.

Mr. Steven Porter, Chairman and CEO of Ceragenix said: "We're very pleased to announce this progress in our licensing efforts. We are very encouraged by the superior performance of the CeraShieldTM antimicrobial coating in comparison to an established antimicrobial device in a rigorous in-vitro testing methodology undertaken by the partner leading to this announcement."
About Ceragenix
Ceragenix Pharmaceuticals, Inc. is a medical device company focused on infectious disease and dermatology. The Company has two base technology platforms; CerageninsTM for treatment of infectious disease and Barrier Repair for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. CerageninTM compounds are active against a broad range of gram positive and negative bacteria. We have used our CerageninTM technology to formulate CerashieldTM antimicrobial coatings for medical devices. All CerageninTM and CerashieldTM products are currently in the developmental stage. Ceragenix's patented Barrier Repair technology, invented by Dr. Peter Elias, is the platform for the development of EpiCeram® which is currently being marketed by Promius Pharmaceuticals (a wholly owned subsidiary of Dr. Reddy's Laboratories) in the United States under an exclusive supply and distribution agreement. For additional information on Ceragenix, please visit www.ceragenix.com.
FORWARD LOOKING STATEMENTS FOR CERAGENIX.
This press release may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, the following: the ability of the Company to fund its operations beyond September 2009; the ability of the Company to successfully negotiate an exclusive license agreement with its partner; the ability of our partner to successfully develop a product using the CerashieldTM technology; the ability of the Company to raise sufficient capital to finance its operations and planned activities including completing development of its CerageninTM technology; the ability of the Company to meet its obligations under the supply and distribution agreement with Dr. Reddy's Laboratories including having sufficient working capital to fulfill purchase orders within the timeframes required by the agreement; the ability of the Company to service its outstanding convertible debt obligations; receiving the necessary marketing clearance approvals from the United States Food and Drug Administration (the "FDA"); successful clinical trials of the Company's planned products including the ability to enroll the studies in a timely manner, patient compliance with the study protocol, and a sufficient number of patients completing the studies; the ability of the Company to commercialize its planned products; the ability of the Company to successfully manufacture its products in commercial quantities (through contract manufacturers); market acceptance of the Company's planned products, the Company's ability to successfully develop its licensed compounds, alone or in cooperation with others, into commercial products, the ability of the Company to successfully prosecute and protect its intellectual property, general economic conditions in the United States and elsewhere, and the Company's ability to hire, manage and retain qualified personnel. The aforementioned factors do represent an all inclusive list. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained in this press release. In particular important factors that could cause actual results to differ materially from our forward-looking statements including general economic factors, business strategies, the state of capital markets, regulatory conditions, and other factors not currently known to us, may be significant, now or in the future, and the factors set forth in this press release may affect us to a greater extent than indicated. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in this press release and in other documents that we file from time to time with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2008, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K to be filed in 2009. Except as required by law, we do not undertake any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contacts: Ceragenix Pharmaceuticals, Inc.
Steven Porter, 720-946-6440
Chairman and CEO





Stock Information
Symbol: OTCBB: CGXP 52 Week Range ($US) $0.16-$1.25Market Capitalization: 4.35 M Shares Outstanding: 18.12 M Sign Up for our client information at www.emergingmarketsllc.com
www.themicrocapreport.com
ContactCeragenix Pharmaceuticals, Inc
1444 Wazee Street, Suite 210Denver, Colorado 80202Phone: 720.946.6440Fax: 303.534.1860
Emerging Markets Consulting, LLC ("EMC") prepares and/or assists others in preparing and publishing oral and written information on selected companies (the "Profiled Companies") and/or their securities (the "Securities") in various contexts, including but not limited to corporate and business profiles, summaries, reports, and press releases (hereafter referred to as the "Corporate Information") through various methods including but not limited to: (a) facsimile; (b) email; (c) mail and courier; (d) world wide web, including but not limited to EMC's website at www.emergingmarketsllc.com; and (e) personal contact at trade shows, business luncheons, seminars and/or meetings. The Corporate Information may be disseminated to broker-dealers, members of the general public, and the financial community (collectively the "Recipients") at the direction of the Profiled Companies and should be used by the Recipients for informational purposes only.EMC and/or its principals, affiliates and representatives receive cash and/or compensation in the Securities in connection with preparation and dissemination of the Corporate Information. EMC did not pay cash consideration for the Securities that it holds (other than payments that may be made by EMC to the Profiled Companies for the exercise of warrants), and any of the Securities held by EMC were issued in exchange for EMC's services. Because EMC is a Shareholder of the Profiled Companies, EMC may have a conflict of interest with the Recipients as well as the Profiled Companies. Independent of any compensation that EMC and/or its principals, affiliates, and representatives may receive, EMC and/or its principals, affiliates, and representatives may at any time purchase and/or sell the Securities, including simultaneous with the publication or distribution of the Corporate Information. The buying and selling of the Securities by EMC and/or its principals, affiliates, and representatives may negatively effect the price of the Securities or cause the price of the securities to increase or decrease or become unstable.EMC does not express any opinions, recommendations or viewpoints regarding the Profiled Companies or the Securities, and has not conducted due diligence of any data or information contained in the Corporate Information. The Corporate Information is based solely upon data and information provided by the Profiled Companies and EMC does not endorse, independently verify, or assert the truthfulness, completeness, accuracy or reliability of the Corporate Information. EMC conducts no due diligence of any type of the Profiled Companies or the Securities. Recipients should not rely on the data or information contained in the Corporate Information in making an investment decision and should conduct their own research of the Profiled Companies. The Recipients should not assume that material changes have not occurred since the publication and/or dissemination of in the Corporate Information. Each of the Recipients should consult with his or her legal, accounting, tax and financial advisers regarding any investment in the Profiled Companies or the Securities.EMC is not a registered investment advisor or registered securities broker dealer and no information contained within the Corporate Information should be construed as investment advice or as a solicitation to offer, purchase or sell the Securities. The Securities may be thinly traded and not listed on any national securities exchange and involve an extremely high degree of risk. Because the Securities are penny stocks, they are subject to the Securities and Exchange Commission's penny stock rules, and as such, any investment in the Securities involves a high degree of risk and it may be difficult for any investor or Shareholder to resell the Securities. An investment in the Securities could result in the loss of some or all of an investment.Recipients should (with the assistance of their legal and financial advisors) review Securities and Exchange Commission ("SEC") filings regarding the Profiled Companies that are SEC reporting issuers. These SEC filings are available for review at www.sec.gov. Recipients should review investment guides that are available at the same SEC website and the National Association of Security Dealers website at www.nasd.com.Statements contained in the Corporate Information that are not historical facts are forward looking statements that involve risks and uncertainties and may be identified by the use of terminology such as "believes", "expects", "may", "will", or "should", or "anticipates". Such statements should be read as being applicable to all related forward looking statements wherever they appear in any of the Corporate Information. The actual results of a Profiled Company's operations, financial condition or other aspects of its business could differ materially from those discussed in the Corporate Information.The issuance of the Securities to EMC may cause shareholders and/or investors of the Profiled Companies to experience immediate and substantial dilution of their holdings and/or investments in the Profiled Companies. Future securities issuances to EMC for services may also result in a reduction of (i) the book value or market price of the Profiled Companies' securities, (ii) shareholder voting power; and (iii) each shareholder's proportionate ownership of any Profiled Company.Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below:

Disclaimer EMC has a June 16, 2009 contract to provide Investor Relations services for Ceragenix Pharmaceuticals, Inc. for a six month period. The company is to pay EMC 60,000 restricted shares of Series B Preferred Stock at the beginning of each 3 month service period. EMC has been paid a total of 60,000 restricted shares of Series B Preferred Stock.

No comments:

Post a Comment